Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07731204
Starting soon Not applicable

Impact of the Receptive Music Intervention Tool (MUSIC CARE©) on Changes in the Functional Abilities of Patients With Chronic Low Back Pain

NCT07731204 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Not applicable
Started
2026-10-01
Last updated
2026-07-28

Condition(s) studied

Low Back PainKinesiophobia (Fear of Movement)Chronic Low-back Pain (cLBP)

Investigational drug(s) / intervention(s)

Receptive Music Therapy

Receptive Music Therapy: MUSIC CARE© is a Class 1 validated medical device delivering personalized receptive music therapy based on hypnoanalgesia principles. Each session follows a standardized "U-sequence" protocol comprising three phases: an induction phase with gradually decreasing tempo and orchestral complexity; a deep relaxation phase with slow tempo and minimal instrumentation; and a progressive awakening phase. Sessions are set at 20 minutes, administered daily before standard rehabilitation sessions throughout the 5-to-6-week day hospital stay. The sequence is pre-personalized by the investigator according to participant musical preferences collected at inclusion. The participant is seated alone in a dedicated room, wearing headphones connected to the MUSIC CARE© tablet.

Study summary

Brief Summary The goal of this clinical trial is to learn if MUSIC CARE©, a music-based therapy tool, can improve the physical abilities of people with chronic low back pain (back pain that lasts more than 3 months).

The main questions it aims to answer are:

Does MUSIC CARE© help participants better perform their daily activities? Does MUSIC CARE© lower the fear of movement in participants? Does MUSIC CARE© help participants return to work?

Why this study? Chronic low back pain is a leading cause of disability and absence from work. Physical rehabilitation is the recommended treatment. However, many participants develop a fear of movement. This fear slows down their recovery and limits the benefits of rehabilitation.

MUSIC CARE© is a digital music tool. It uses specially designed music to help participants relax and feel less pain. Researchers believe that using MUSIC CARE© before rehabilitation sessions may help participants move more freely and recover better.

How does the study work?

Researchers will compare two groups of participants:

Group 1: follows a standard rehabilitation program with MUSIC CARE© Group 2: follows a standard rehabilitation program without MUSIC CARE© This comparison will show whether MUSIC CARE© brings added benefits.

Participants will:

Take part in a rehabilitation program for 5 to 6 weeks Use MUSIC CARE© before each therapy session (Group 1 only). Complete questionnaires about their pain, fear of movement, and ability to perform daily activities.

Be followed for 6 months after the program ends, including an assessment of their return to work.

What could this study change? If results are positive, this study could confirm that MUSIC CARE© is a useful non-drug tool to support rehabilitation for people with chronic low back pain. It could help bring this approach into standard care programs, with no additional medication.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with chronic low back pain by a Physical Medicine and Rehabilitation (PMR) physician, defined as lumbar pain and/or pain radiating to the lower limb that affects daily and professional activities and has lasted more than 3 months * If surgery was performed, it must have been done at least 3 months before entering the study * Adult (18 years of age or older) admitted to the day hospital at Clinique Saint-Roch for a chronic low back pain rehabilitation program * Considered able to return to work, as assessed by the PMR physician during the pre-admission consultation, with no medical contraindication to resuming professional activity * Affiliated with a French social security scheme * Has given written informed consent to participate in the study Exclusion Criteria: * Hearing impairment that would prevent the use of the MUSIC CARE© device * Medical contraindication to hydrotherapy (balneotherapy) * Symptomatic disc herniation * Vertebral fracture or history of recent vertebral fracture within the past 2 years * Unstable spondylolisthesis * Disc-vertebral infection (spondylodiscitis) * Inflammatory rheumatic disease such as ankylosing spondylitis (spondyloarthritis) or rheumatoid arthritis * Constitutional connective tissue disorder such as Ehlers-Danlos syndrome or Marfan syndrome * Severe, unstabilized, or decompensated psychiatric disorder, including psychotic disorders, acute-phase bipolar disorder, or severe major depressive episode * Central nervous system neurological disease such as multiple sclerosis, stroke, or Parkinson's disease * Peripheral neuropathy of the lower limbs * Unstabilized cardiovascular disease * Active cancer treatment or cancer diagnosis within the past 2 years * Surgery for a reason other than low back pain within the past 6 months * Currently retired (not in active employment) * Currently enrolled in another interventional research study * Persons under legal protection as defined by Articles L.1121-5 to L.1121-8 of the French Public Health Code, including: * Persons under guardianship, curatorship, or judicial protection * Minors (under 18 years of age) * Pregnant or breastfeeding women * Any person subject to a legal protection measure or unable to freely provide informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinique Saint-Roch - LNA SANTE Roncq France

More LNA SANTE trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07731204 on ClinicalTrials.gov ↗ ← All trials in France